JP2023126440A5 - - Google Patents

Download PDF

Info

Publication number
JP2023126440A5
JP2023126440A5 JP2023115231A JP2023115231A JP2023126440A5 JP 2023126440 A5 JP2023126440 A5 JP 2023126440A5 JP 2023115231 A JP2023115231 A JP 2023115231A JP 2023115231 A JP2023115231 A JP 2023115231A JP 2023126440 A5 JP2023126440 A5 JP 2023126440A5
Authority
JP
Japan
Prior art keywords
compound
radiolabeled
medicament
cancer
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023115231A
Other languages
English (en)
Japanese (ja)
Other versions
JP7534498B2 (ja
JP2023126440A (ja
Filing date
Publication date
Priority claimed from JP2019104379A external-priority patent/JP6997135B2/ja
Application filed filed Critical
Publication of JP2023126440A publication Critical patent/JP2023126440A/ja
Publication of JP2023126440A5 publication Critical patent/JP2023126440A5/ja
Application granted granted Critical
Publication of JP7534498B2 publication Critical patent/JP7534498B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023115231A 2012-09-25 2023-07-13 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト Active JP7534498B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
US61/705,513 2012-09-25
JP2019104379A JP6997135B2 (ja) 2012-09-25 2019-06-04 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
JP2021154188A JP7358430B2 (ja) 2012-09-25 2021-09-22 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021154188A Division JP7358430B2 (ja) 2012-09-25 2021-09-22 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2023126440A JP2023126440A (ja) 2023-09-07
JP2023126440A5 true JP2023126440A5 (https=) 2023-10-17
JP7534498B2 JP7534498B2 (ja) 2024-08-14

Family

ID=49887190

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015534625A Active JP6562838B2 (ja) 2012-09-25 2013-09-25 Grpr陽性ガンの診断画像及び治療適用のための放射標識したgrprアンタゴニスト
JP2019104379A Active JP6997135B2 (ja) 2012-09-25 2019-06-04 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
JP2021154188A Active JP7358430B2 (ja) 2012-09-25 2021-09-22 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
JP2023115231A Active JP7534498B2 (ja) 2012-09-25 2023-07-13 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2015534625A Active JP6562838B2 (ja) 2012-09-25 2013-09-25 Grpr陽性ガンの診断画像及び治療適用のための放射標識したgrprアンタゴニスト
JP2019104379A Active JP6997135B2 (ja) 2012-09-25 2019-06-04 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
JP2021154188A Active JP7358430B2 (ja) 2012-09-25 2021-09-22 Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102190005B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL276300B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
KR20220063218A (ko) * 2019-09-16 2022-05-17 노파르티스 아게 안정한 농축 방사성 약제학적 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識grprアンタゴニスト
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2026083422A1 (en) * 2024-10-20 2026-04-23 Starget Pharma Ltd Cyclic grpr binding peptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist
US4943561A (en) * 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IE903958A1 (en) 1989-11-06 1991-05-08 Erba Carlo Spa Reduced irreversible bombesin antagonists
WO1993016105A1 (en) 1992-02-07 1993-08-19 Merrell Dow Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
IN2013MN01188A (https=) 2010-11-22 2015-07-10 Piramal Imaging Sa
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) * 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Similar Documents

Publication Publication Date Title
JP2023126440A5 (https=)
JP2024071370A5 (https=)
JP2024516371A5 (https=)
JP2021530565A5 (https=)
CN115667238A (zh) 一种五并五元环衍生物及其在医药上的应用
JP2021530451A5 (https=)
JP2005521713A5 (https=)
JP2007302689A5 (https=)
JP2022512482A5 (https=)
JP2006511587A5 (https=)
CN113784970A (zh) Erk抑制剂及其应用
JP2010540556A5 (https=)
JP2019524883A5 (https=)
JP2016501221A5 (https=)
JP2011518833A5 (https=)
JP2020511467A5 (https=)
JP2008526765A5 (https=)
JP2009535462A5 (https=)
JP2015535831A5 (https=)
JP2009502743A5 (https=)
JP2013512277A5 (https=)
JP2014530818A5 (https=)
JP2020507589A5 (https=)
JP2023531709A5 (https=)
JP2018145180A5 (https=)